Singapore General Hospital, Novartis ink MoU on clinical trials

The partnership focuses on radioligand therapy, cell therapy, and early-phase trials.

Singapore General Hospital (SGH) and Novartis Singapore have signed a memorandum of understanding (MoU) to advance clinical trials and research.

The partnership focuses on areas, such as radioligand therapy, cell therapy, and early-phase trials.

The MoU extends an existing partnership with SGH, which has facilitated up to 67 clinical trials, nearly half within the oncology field.